NFKB1 and cancer: Evidence that inhibition of acidic bile‐induced NF‐κB activation effectively reverses the altered cancer‐related miRNA phenotype will encourage the in vivo application of NF‐κB inhibitors, as possible preventers of acidic bile effect in hypopharyngeal mucosa.